Live video webcast on Tuesday, June 18th at 3:00 PM ET
HOUSTON, June 12,
2024 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage
pharmaceutical company with a broad portfolio of drug candidates
targeting hard-to-treat tumors and viruses, today announced that it
will present at the Virtual Investor Pitch Conference on
June 18, 2024 at 3:00 PM ET.
As part of the event, Walter
Klemp, Chairman and Chief Executive Officer of Moleculin,
will provide an "elevator pitch" and outline the Company's upcoming
milestones. Additionally, investors and interested parties will
have the opportunity to submit questions live during the event.
Participating companies will answer as many questions as possible
in the time allowed.
A live video webcast of the event will be available on the
Events page under the Investors section of the Company's website
(moleculin.com). A webcast replay will be available two hours
following the live presentation and will be accessible for 90
days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company with a growing pipeline, including Phase 2 clinical
programs, for hard-to-treat tumors and viruses. The Company's lead
program, Annamycin is a next-generation anthracycline designed to
avoid multidrug resistance mechanisms and to eliminate the
cardiotoxicity common with currently prescribed anthracyclines.
Annamycin is currently in development for the treatment of relapsed
or refractory acute myeloid leukemia (AML) and soft tissue sarcoma
(STS) lung metastases. All interim and preliminary data related to
its active clinical trials are subject to change.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers. Moleculin is also engaged in the development of a
portfolio of antimetabolites, including WP1122 for the potential
treatment of viruses, as well as certain cancer indications.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-virtual-investor-pitch-conference-302170145.html
SOURCE Moleculin Biotech, Inc.